A positive trial is not a class effect.
A negative trial is not a class verdict.
NIAGARA vs KEYNOTE-866/ENERGIZE: the regimen matters.
Which patients truly benefit?
@myESMO @OncoAlert @OpenMedicineHQ #ESMO26
550 浏览 · 9 赞 · 4 转发 · 1 回复
Perioperative pembrolizumab (pembro) or placebo (pbo) + neoadjuvant cisplatin (cis) and gemcitabine (gem) in participants (pts) with muscle-invasive bladder cancer (MIBC): the double-blind, phase 3 KEYNOTE-866 study
https://esmocongress.esmo.org#ESMO26: No significant increase in event-free survival seen with peri-operative pembrolizumab or nivolumab in the KEYNOTE-866 or ENERGIZE #ClinicalTrials of resectable muscle-invasive #BladderCancer (#MIBC), as discussed by @y_loriot 🔗 https://ow.ly/TbzF50ZZ0s2 #InsightsbyESMO在 X 查看被引用的帖子
- Michiel Strijbos@StrijbosMichiel
A positive trial is not a class effect. A negative trial is not a class verdict. The regimen is the question. The patient is the answer we have not yet learned to ask. Benefit is not the average of the curve. It is the quiet alignment between residual risk and the language the tumor still speaks.
来源：Yüksel Ürün · x.com